Optical coherence tomography compared with colposcopy for assessment of vaginal epithelial damage: A randomized controlled trial

Obstetrics and Gynecology

Volumn 118, Issue 6, 2011, Pages 1354-1361

  Vincent, Kathleen L ^{a,b,c,d,e,f,g}   Stanberry, Lawrence R ^{a,b,c,d,e,f,g}   Moench, Thomas R ^{a,b,c,d,e,f,g}   Breitkopf, Carmen Radecki ^{a,b,c,d,e,f,g}   Loza, Melissa L ^{a,b,c,d,e,f,g}   Wei, Jingna ^{a,b,c,d,e,f,g}   Grady, James ^{a,b,c,d,e,f,g}   Paull, Jeremy ^{a,b,c,d,e,f,g}   Motamedi, Massoud ^{a,b,c,d,e,f,g}   Rosenthal, Susan L ^{a,b,c,d,e,f,g}  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b College of Physicians and Surgeons ^*  (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d REPROTECT INC   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^g Starpharma Holdings Limited   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYETHYLCELLULOSE; NONOXINOL 9; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; COLPOSCOPY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INTERMETHOD COMPARISON; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; THICKNESS; VAGINA EPITHELIUM; VAGINAL INJURY;

ADULT; COLPOSCOPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; NONOXYNOL; SPERMATOCIDAL AGENTS; TOMOGRAPHY, OPTICAL COHERENCE; VAGINAL DISEASES; YOUNG ADULT;

EID: 81855161515     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e318238f563     Document Type: Article

References (32)

1. World Health Organization. Global summary of the HIV/AIDS epidemic 2009. Available at: http://www.who.int/hiv/data/en/. Retrieved March 7, 2011.
2. Karim QA, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329: 1168-74.
3. AVAC-Global Advocacy for HIV Prevention. Microbicide clinical trials. Available at: http://www.avac.org/. Retrived March 7, 2011.
4. Stafford MK, Ward H, Flanagan A, Rosenstein IJ, Taylor-Robinson D, Smith JR, et al. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:327-31.
5. Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008;3:e1474.
6. Van Damme L, Govinden R, Mirembe FM, Guédou F, Solomon S, Becker ML, et al. CS Study Group: Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008;359:463-72.
7. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial. Lancet 2002;360:971-7. (Pubitemid 35284107)
8. Kreiss J, Ngugi E, Holmes K, Ndinya-Achola J, Waiyaki P, Roberts PL, et al. Efficacy of nonoxynol9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 1992;268:477-82.
9. Van Damme L, Chandeying V, Ramjee G, Rees H, Sirivongrangson P, Laga M, et al. Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. COL-1492 Phase II Study Group. AIDS 2000;14: 85-8. (Pubitemid 30072081)
10. Guido RS, Cardinal-Busse BR, McIntyre-Seltman K, Hillier SL, Krohn MA, Murray PJ, et al. Colposcopically obtained images of vulvar, vaginal, and cervical epithelium for assessment of safety of intravaginal agents among normal adolescent females: comparison with in vivo exam and interobserver agreement. J Lower Gen Tract Dis 2003;7:259-63. (Pubitemid 37336597)
11. Michel RG, Kinasewitz GT, Fung KM, Keddissi JI. Optical coherence tomography as an adjunct to flexible bronchoscopy in the diagnosis of lung cancer: a pilot study. Chest 2010;138: 984-8.
12. Vincent KL, Bell BA, Rosenthal SL, Stanberry LR, Bourne N, Sweeney YT, et al. Application of optical coherence tomography for monitoring changes in cervicovaginal epithelial morphology in macaques: potential for assessment of microbicide safety. Sex Transm Dis 2008;35:269-75. (Pubitemid 351619530)
13. Vincent KL, Bourne N, Bell BA, Vargas G, Tan A, Cowan D, et al. High resolution imaging of epithelial injury in the sheep cervicovaginal tract: a promising model for testing safety of candidate microbicides. Sex Transm Dis 2009;36:312-8.
14. Tien D, Schnaare R, Kang F, Cohl G, McCormick TJ, Moench TR, et al. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses 2005;21:845-53. (Pubitemid 43150316)
15. Schwartz JL, Ballagh SA, Kwok C, Mauck CK, Weiner DH, Rencher WF, et al. Fourteen-day safety and acceptability study of the universal placebo gel. Contraception 2007;75:136-41. (Pubitemid 46108723)
16. Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T, et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 2011;25:957-66.
17. Harwood B, Meyn LA, Ballagh SA, Raymond EG, Archer DF, Creinin MD. Cervicovaginal colposcopic lesions associated with 5 nonoxynol-9 vaginal spermicide formulations. Am J Obstet Gynecol 2008;198:32.e1-7.
18. Dumville JC, Hahn, Miles JNV, Torgerson DJ. The use of unequal randomisation ratios in clinical trials: A review. Contemp Clin Trials 2006;27:1-12. (Pubitemid 41758434)
19. WHO/CONRAD Manual for the standardization of colposcopy for the evaluation of vaginal products, Update 2004. Punta Cana (Dominican Republic): CONRAD/WHO; 2004.
20. Breitkopf CR, Loza M, Vincent K, Moench T, Stanberry LR, Rosenthal SL, et al. Perceptions of reimbursement for clinical trial participation. J Exp Res Human Res Ethics 2011;6:31-8
21. Radecki Breitkopf C, Loza MA, Vincent K, Moench T, Stanberry LR, Rosenthal SL. Acceptability of optical coherence tomography and abstinence requirements among women participating in microbicide safety trials. Sex Transm Dis 2011 Aug 30 [epub ahead of print].
22. Vincent KL, Levine L, Bell B, Yandell R, Motamedi M. Optical coherence tomography in the evaluation of cervical dysplasia. Oral presentation at the 34th Annual Meeting of the Society of Gynecologic Oncologists, February 1-4, 2003, New Orleans, LA. Gynecol Oncol 2003;88:174-5.
23. Escobar PF, Rojas-Espailla L, Tisch S, Enerson C, Brainard J, Smith J, et al. Optical coherence tomography as a diagnostic aid to visual inspection and colposcopy for preinvasive and invasive cancer of the uterine cervix. Int J Gynecol Cancer 2006;16:1815-22. (Pubitemid 44470041)
24. Mauck CK, Callahan MM, Baker J, Arbogast K, Veazey R, Stock R, et al. The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy. Contraception 1999;60:15-24. (Pubitemid 29505351)
25. Patton DL, Thwin SS, Meier A, Hooton TM, Stapleton AE, Eschenbach DA. Epithelial cell layer thickness and immune cell populations in the normal human vagina at different stages of the menstrual cycle. Am J Obstet Gynecol 2000;183: 967-73.
26. Marx PA, Spira AI, Gettie A, Dailey PJ, Veazey RS, Lackner AA, et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996;2:1084-9. (Pubitemid 26338626)
27. Smith SM, Mefford M, Sodora D, Klase Z, Singh M, Alexander N, et al. Topical estrogen protects against SIV vaginal transmission without evidence of systemic effect. AIDS 2004;18: 1637-43. (Pubitemid 39095780)
28. Wira CR, Fahey JV. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS 2008;22:1909-17.
29. Yeaman GR, Asin S, Weldon S, Demian DJ, Collins JE, Gonzalez JL, et al. Chemokine receptor expression in the human cervix: implications for infections by the human immunodeficiency virus-type I. Immunology 2004;113:524-33. (Pubitemid 39593371)
30. Van de Wijgert JH, Kilmarx PH, Jones HE, Karon JM, Chaikummao S. Differentiating normal from abnormal rates of genital epithelial findings in vaginal microbicide trials. Contraception 2008;77:122-9.
31. ONeill E, Reeves MF, Creinin MD. Baseline colposcopic findings in women entering studies on female vaginal products. Contraception 2008;78:162-6.
32. Ballagh SA, Mauck CK, Henry D, Archer DF, Abercrombie T, Callahan MM, et al. A comparison of techniques to assess cervicovaginal irritation and evaluation of the variability between two observers. Contraception 2004;70:241-9. (Pubitemid 39119987)